Amgen's Sjögren's Drug Clears Its Biggest Hurdle Yet
Amgen's Sjögren's Drug Clears Its Biggest Hurdle Yet
Amgen has reported that its investigational fusion protein dazodalibep met the primary endpoint of a pivotal Phase 3 trial in Sjögren’s disease. In the OASIZ-301 study, patients with moderate-to-severe systemic disease activity who received dazodalibep showed statistically significant and clinically meaningful improvement on the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) at week 48 compared with placebo. Improvements were observed as early as week 4. The result clears the largest clinical hurdle so far for a program that could become the first FDA-approved systemic therapy specifically for moderate-to-severe systemic Sjögren’s disease, a chronic autoimmune condition that currently lacks approved disease-modifying options.
The Unmet Need in Sjögren’s Disease
Sjögren’s disease causes the immune system to attack moisture-producing glands, leading to profound dryness of the eyes and mouth, fatigue and chronic pain. In a substantial subset of patients the disease also produces systemic activity across multiple organ domains. It affects roughly 1% of the global population and predominantly women. Management today relies largely on symptomatic treatments and non-specific anti-inflammatory approaches; no therapy is approved in the United States to modify moderate-to-severe systemic disease activity.
How Dazodalibep Works
Dazodalibep is a fusion protein that targets the CD40 ligand (CD40L), a key co-stimulatory pathway involved in T-cell and B-cell interactions that drive autoimmune inflammation. By interrupting this pathway, the drug aims to reduce the systemic immune activity measured by ESSDAI, a composite score spanning 12 organ domains. The molecule entered Amgen’s pipeline through the Horizon Therapeutics acquisition of Viela Bio assets.
OASIZ-301 Design and Topline Outcome
OASIZ-301 is a randomised, double-blind, placebo-controlled Phase 3 trial that enrolled approximately 620–650 adults with Sjögren’s disease and an ESSDAI score of 5 or higher, indicating moderate-to-severe systemic activity. The primary endpoint was change in ESSDAI at week 48. Amgen reported that dazodalibep achieved both statistical significance and clinical meaningfulness on this measure. Most adverse events were mild to moderate; discontinuations were limited. Detailed efficacy and safety data are scheduled for presentation at an upcoming medical meeting.
A Second Pivotal Trial Still Pending
A companion Phase 3 study, OASIZ-303, is evaluating dazodalibep in patients who have significant symptom burden but lower systemic disease activity. Results from that trial are expected in the fourth quarter of 2026. Together the two studies are intended to cover the spectrum of patients most in need of systemic therapy. A long-term extension is open to participants from both trials.
Why This Result Matters
Sjögren’s has historically been a difficult indication for drug development, with high placebo responses and heterogeneous disease biology. A clear Phase 3 win on a validated systemic activity endpoint therefore represents a meaningful de-risking event. Analysts noted the result as encouraging given those development challenges. For patients and clinicians, the data raise the prospect of a first targeted systemic option; for Amgen, they revitalise a pipeline asset acquired through the Horizon transaction that had yet to deliver a late-stage success of this magnitude.
Next Steps and Competitive Context
Amgen will present full data, continue the second pivotal trial, and engage regulators on a potential path to approval. If ultimately successful, dazodalibep would enter a market with no direct approved competitors for systemic disease modification, although other mechanisms are in earlier development. Commercial uptake would depend on the magnitude of benefit shown in the detailed data, durability, safety in broader use, and how the drug performs across both high- and lower-systemic-activity populations.
Outlook
By meeting its primary endpoint in OASIZ-301, Amgen’s dazodalibep has cleared the biggest clinical hurdle yet in the quest for an approved systemic therapy for moderate-to-severe Sjögren’s disease. The pending OASIZ-303 readout and the full presentation of 301 data will determine how robust the overall Phase 3 package looks to regulators and the market. For a disease that has long lacked disease-modifying options, the positive topline result offers the clearest evidence to date that a CD40L-directed approach can meaningfully reduce systemic disease activity.
Sources
Copper Sulphate Anhydrous
Found this useful?
